Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:36:53 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:DRMA from 2023-04-27 to 2024-04-26 - 17 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-27 16:07U:DRMANews ReleaseDermata to Present at the Emerging Growth Conference on April 3, 2024
2024-02-06 07:00U:DRMANews ReleasePresenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
2024-02-01 09:03U:DRMANews ReleaseDermata to Present at the Emerging Growth Conference on February 7, 2024
2024-01-04 16:06U:DRMANews ReleaseDermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
2023-12-20 16:08U:DRMANews ReleaseDermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
2023-11-16 13:32U:DRMANews ReleaseDermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
2023-11-16 08:03U:DRMANews ReleaseDermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
2023-11-09 16:08U:DRMANews ReleaseDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2023-08-31 18:18U:DRMANews ReleaseDermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-10 16:16U:DRMANews ReleaseDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
2023-06-27 09:02U:DRMANews ReleaseDermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
2023-06-13 16:15U:DRMANews ReleaseDermata Therapeutics to Participate in the Healthcare Virtual Conference ‚  Presented by Maxim Group LLC and hosted by M-Vest ‚  on Tuesday, June 20th ‚  to Thursday, June 22nd at 9:00 A.M. ET
2023-06-08 09:02U:DRMANews ReleaseJournal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
2023-05-26 16:00U:DRMANews ReleaseDermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
2023-05-24 08:01U:DRMANews ReleaseDermata Therapeutics ‚  Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
2023-05-11 16:06U:DRMANews ReleaseDermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
2023-05-10 11:48U:DRMANews ReleaseDermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studies